828 INDEX
corticosteroids (Continued)
for eosinophilic granuloma, 355, 364
for epidermolysis bullosa acquisita, 197
for epitheliotropic lymphoma, 369
for histiocytic proliferative disorders, 386
for insect bites and stings, 246, 247
for keratinization disorders, 438, 439
for lupus erythematosus, 472
for mast cell tumors, 498
for otitis, 549, 550
for pemphigus complex, 195–196
precautions, 197, 625
for pyoderma, 217
for sarcoptid mites, 637, 638
for sterile nodular panniculitis, 566
for uveodermatologic syndrome, 693
see alsodexamethasone; methylprednisolone;
prednisolone
corticotropinseeACTH
cortisol-creatinine ratio, urine, 398–399, 410
Cortrosynseecosyntropin
cosyntropin, 763
cowpox virus infection, feline, 64, 712
COX-2, 365
COX-2 selective inhibitors, 578, 623, 679
crusting dermatoses, 63–65
crusts, 12, 15
biopsy technique, 37
cytology, 46
histopathology, 39
cryotherapy, for sporotrichosis, 661
cryptococcosis
clinical features,118,521–522,528–531
course and prognosis, 526
diagnostics, 523, 524, 533
therapeutics, 524–526
Cryptococcus gattii, 521
Cryptococcus neoformans, 521, 533
Ctenocephalides felis felis, 239
CT scanseecomputed tomography
culture and identification, 28–31
bacteria, 28, 30–31,34–35
deep mycoses, 524, 534
dermatophytes, 28–30,33–34,322–323,334–335
Malassezia, 482, 493
mycobacteria, 514
otitis, 547
culture media, dermatophyte, 28
curly-coated retriever, 735
Cushing’s syndromeseehyperadrenocorticism
cutaneous adverse drug reactionsseedrug reactions,
cutaneous adverse
cutaneous adverse food reactionsseefood reactions,
cutaneous adverse
cutaneous and renal glomerular vasculopathy of
greyhounds, 63, 699
cutaneous epitheliotropic lymphomasee
epitheliotropic lymphoma, cutaneous
cutaneous lupus erythematosus (CLE), 467–472
clinical features, 469–470,473–478
course and prognosis, 472
diagnostics, 471
exfoliativeseeexfoliative cutaneous lupus
erythematosus
mucous membrane (MCLE), 468, 469–470, 471,
476
signalment/history, 468–469
therapeutics, 471–472
vesicular (VCLE), 468, 470, 471
see alsodiscoid lupus erythematosus
cutaneous lymphocytosisseelymphocytosis, cutaneous
cutaneous mucinosisseemucinosis, cutaneous
cutaneous nonepitheliotropic lymphoma (CnEL),
365–370
clinical features, 366,370–371
diagnostics, 368
differential diagnosis, 367, 383
etiology/pathophysiology, 365
prognosis, 370
signalment/history, 366
therapeutics, 369
cutaneous T-cell lymphoma (CTCL), 365–370, 613
see alsocutaneous nonepitheliotropic lymphoma;
epitheliotropic lymphoma
cyclic hematopoiesis, canine, 66
cyclic neutropenia, canine, 66
cyclooxygenase-2seeCOX-2
cyclophosphamide, 763
adverse effects,73, 198
for cutaneous lymphoma, 369
for mast cell tumors, 498, 499
cyclosporine, 764
for anal furunculosis/perianal fistula, 163–164, 168
for atopic disease, 180–181
for claw disorders, 594
for contact dermatitis, 268
for cutaneous adverse drug reactions, 275
for dermatomyositis, 315
for eosinophilic granuloma (complex), 355
for epidermolysis bullosa acquisita, 197
for keratinization disorders, 438
for lupus erythematosus, 472
for panniculitis, 566
for pemphigus complex, 196
for reactive histiocytosis, 386
for sebaceous adenitis, 650
side effects, 198
for uveodermatologic syndrome, 694
for vasculitis, 702
Cydectinseemoxidectin
cyproheptadine, 234, 764
cysts
cerumen, 562
defined, 13, 21
panniculitis vs, 564
cytokines, in atopic disease, 174–175